Story

The Full Story

AgeSA's 2021–2025 story is unusually quiet for a company operating through 85% CPI prints, a February 2023 earthquake, a 4,000 bps rate cycle and a sector-wide hyperinflation-accounting debate: management said leadership, digitalization, sustainability, people in 2021 and the same four words in 2025, while the financials quietly compounded at an 80%+ nominal CAGR. The real inflection was not a crisis but a shareholder swap — Aviva exited in 2021, Ageas (Belgium) took 40%, the "AgeSA" brand replaced "AvivaSA", and the same CEO (Fırat Kuruca, in seat since Jan 2017) executed a three-phase build: rebrand → life-insurance pivot → health-insurance bolt-on. Credibility is quietly strong — the one public numerical target (FY2022 SFRS NP of ₺850–950M) was hit at ₺875M, and every metric since has beaten its implicit pace. The question is not whether management delivered, but whether the ₺ denominator flattered the delivery.

**Reporting nuance readers should hold onto.** Turkey is a hyperinflationary economy under TAS 29 / IAS 29. SEDDK (the insurance regulator) granted the sector an exemption — AgeSA continues to report historical-cost SFRS figures, and its investor-day numbers use "IFRS excluding inflation accounting effect." All ₺ figures below are **nominal**, so compound growth needs to be read against a 2021–24 CPI CAGR of roughly 58% and a 2025 CPI print of around 31%.

1. The Narrative Arc

Three phases, one CEO, one brand rotation.

No Results

What the arc tells you: AgeSA is a single-CEO, single-strategy company that has spent five years compounding through very loud macro noise. The inflection points came from ownership (Aviva → Ageas) and M&A (Medisa), not from strategy resets.

GWP grew 18x from 2020 to 2025 (₺1.3bn → ₺24.4bn). Net profit grew 20x (₺0.35bn → ₺6.8bn). But 2021–24 Turkish CPI compounded at roughly 58% p.a. — on a real basis the business roughly doubled. That is the honest read.

2. What Management Emphasized — and Then Stopped Emphasizing

Management's themes are remarkably additive: nothing gets dropped, new themes get layered on. The topic-frequency heatmap makes the drift visible.

What the heatmap shows:

Quietly dropped: the Gladly brand positioning — from the opening line of the 2021 annual report to barely a mention by 2025. Classic post-launch brand fatigue; management reverted to financial storytelling.
Newly dominant: Medisa and health insurance. In 2023 this was a one-line mention; by 2025 it is listed among the top-three "Future" initiatives in every earnings deck. The ₺1.4bn cumulative capital injection tells you it is not optional.
Peak-then-fade: inflation accounting (IAS 29) and IFRS 17 — both peaked in 2023–24 as reporting debates and faded once SEDDK confirmed the sector exemption would continue.
Structurally constant: Akbank bancassurance, digitalization, pension leadership. These are the load-bearing themes across all five years.
Strategic add: Aksigorta synergies — a 2024 addition tied to Kuruca's dual-CEO role, signalling Sabancı's intent to run its insurance cluster as a group.

3. Risk Evolution

What moved in the risk discussion — and what did not — is more revealing than the quantum of growth. Between FY2021 and FY2024 the risk framework language is almost identical (seven risk policies, three lines of defense, same Holirisk-GRC platform), but the weight on individual risks shifted.

What became more important:

Inflation went from background noise (FY2021, CPI around 20%) to the single most discussed macro variable (FY2022, CPI peak 85%; FY2023, ₺ rate cycle). It eased slightly in FY2024 as CBRT's orthodox tightening worked.
Earthquake / catastrophe risk appeared as a live line item only in FY2023 after Feb 2023 Kahramanmaraş — not surprising, but worth noting that AgeSA's loan-life book did see policy-extension measures granted by Akbank in the State of Emergency region.
IT / cyber steadily rose from "managed" to a dedicated ISO 22301 BCM framework with an emerging-risk workshop added in 2024.
Conduct risk was introduced as a distinct Board-level policy in FY2023 — AgeSA explicitly renamed "attitude risk" to "conduct risk," aligning with Ageas Group terminology.

What stayed flat: credit risk and liquidity risk. The book is largely funded by policyholder liabilities plus ₺7.9bn of equity against a Solvency I surplus of 198–204%. Balance-sheet risk is genuinely small for a company compounding at 80%+ nominal.

4. How They Handled Bad News

AgeSA does not issue a traditional guidance range, runs no earnings calls, and publishes audio-only results with an earnings-release PDF. That reduces the standard "miss" material — but there are three moments where management had to address friction.

**The earthquake (Feb 2023).** In the FY2022 deck (Mar 2023) management addressed it obliquely, noting sector solidarity and Sabancı Group's ₺12bn relief pledge. In FY2023 the detail became explicit: Ageas Group established a donation fund, loans in the emergency zone were postponed 1–6 months by Akbank, and AgeSA extended policy grace periods. No loss estimate was quantified — but unlike non-life peers the life-insurance book had limited direct exposure. The handling was honest and quietly so.

**The hyperinflation-accounting debate (2023–24).** The pivotal narrative challenge. Turkey's accounting-standard body (KGK) declared 2023 financials subject to IAS 29, but SEDDK granted insurers an exemption. Management picked the "Management Reporting = IFRS excluding inflation accounting" framing for its investor deck — a legitimate but generous choice that makes comparisons with pre-inflation years smoother and makes nominal growth look better. They also disclose full SFRS numbers, so nothing is hidden — but a reader has to work to strip the denominator.

**Expense-ratio pressure (FY2023).** Expense ratio rose from 45.4% (FY2022) to 47.0% (FY2023) as inflation pushed personnel, IT, outsourcing and consultancy costs up. Management flagged this honestly in the FY2023 deck — "general expenses increased 104% mainly due to high inflationary environment." By FY2024 the ratio had *improved* to 42.7% and in FY2025 to 39.2% — operating leverage finally caught up with inflation. This is the most credible single data point on execution.

No walk-backs. No guidance cuts. No dropped initiatives that were quietly reversed. The worst-case reading is that AgeSA faced genuinely benign idiosyncratic conditions — high inflation feeds premium growth, Turkey's OKS system delivers captive pension AuM, and Akbank hands them a locked bancassurance channel.

5. Guidance Track Record

AgeSA is not a heavy-forward-guidance company. The earnings decks use directional language ("continue to grow," "leadership," "synergies") rather than quantified targets. Only one hard numerical promise has been made public in the last five years — the FY2022 SFRS net-profit range — and it was hit.

No Results

Credibility score

Credibility Score

Out of

Sole Hard Guidance Hit (₺M)

875

8 / 10. Management hit its only numerical target, never walked back an initiative, grew dividends 10x in three years, and handled inflation/earthquake disclosures honestly. The two points deducted reflect (a) the deliberate framing of "IFRS excluding inflation accounting" as the headline — a legitimate but flattering choice — and (b) the paucity of quantified forward guidance, which makes future credibility easier to maintain simply by not taking risks with the narrative.

6. What the Story Is Now

**The simplest honest statement of the story in April 2026.** AgeSA is the #1 private life-insurance and pension company in Turkey, co-owned 40/40 by Sabancı and Ageas, compounding nominal top-line at 70%+ against ~31% CPI, paying rising dividends (₺1.0bn in 2025), sitting on a 204% Solvency I ratio, and using excess capital to bolt on a health-insurance subsidiary (Medisa, 100% owned, ₺1.4bn capital injected). The bancassurance channel through Akbank is the structural moat; Turkey's auto-enrolment pension system is the structural tailwind.

What has been de-risked since 2021:

Ownership uncertainty — Ageas is an active, committed partner with three board seats and a named Vice-Chairman.
Life-insurance positioning — standalone and credit-linked life are now roughly equal contributors; the book is no longer concentrated in pension fees alone.
Capital adequacy — solvency ratio lifted from 145% (FY2021) to 204% (FY2025) even while paying ₺1bn dividends and injecting ₺1.4bn into Medisa.
Expense discipline — ratio from 48.5% (FY2020) to 39.2% (FY2025) through 85% CPI peaks. Genuine operating leverage.

What still looks stretched — or deserves skepticism:

The ₺ denominator flattery. FY2025 "Management Reporting" net profit of ₺6.8bn at +72% YoY sounds spectacular; against ~31% CPI the real growth is closer to 30%. Comparisons across 2021–25 should be done on a real basis.
Reliance on Akbank. A single bancassurance counterparty supplies the largest share of production. The partnership is exclusive and long-dated, but it is also concentration.
Medisa is unproven. ₺1.4bn of capital has gone in; the consolidation P&L impact in FY2024 was a loss of ₺43.6M. Health insurance in Turkey is a crowded, regulated-margin business. Execution here will shape the 2026–27 narrative more than anything management did in 2021–25.
Dual-CEO role. Kuruca's appointment as Aksigorta CEO (Jun 2024) on top of AgeSA CEO creates obvious synergy stories but also obvious bandwidth concerns. Investors should watch whether Ageas — who has not hidden its preference for separate CEOs in other markets — renegotiates.

What to believe vs discount:

Believe: leadership position in PPS (durable), the life-insurance pivot (structural), capital returns (demonstrated), and the expense-leverage trajectory (measured).
Discount: any growth rate that is not explicitly real-CPI-adjusted; any "future" storyline (Medisa, Supplemental Pension System, end-to-end digital transformation) whose timing isn't tied to a number.

The story is simpler, not more stretched, than it was in 2021. That is the quiet achievement of this management team.